STOCK TITAN

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) will report its third quarter 2022 financial results on November 1, 2022, before U.S. market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results. Investors can dial (800) 225-9448 domestically or +1 (203) 518-9708 internationally to participate. Harmony focuses on innovative therapies for rare neurological diseases, emphasizing the importance of empathy and innovation in their approach.

Positive
  • None.
Negative
  • None.

PLYMOUTH MEETING, Pa., Oct. 18, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2022 financial results on Tuesday, November 1, 2022, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on November 1, 2022, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial (800) 225-9448 (domestic) or +1 (203) 518-9708 (international), and reference passcode HRMYQ322. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences 
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com

Harmony Biosciences Media Contact: 
Nancy Leone 
215-891-6046 
nleone@harmonybiosciences.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-third-quarter-2022-financial-results-on-november-1-2022-301651322.html

SOURCE Harmony Biosciences

FAQ

When will Harmony Biosciences report its Q3 2022 financial results?

Harmony Biosciences will report its Q3 2022 financial results on November 1, 2022.

What time is the Harmony Biosciences conference call on November 1, 2022?

The conference call is scheduled for 8:30 a.m. ET on November 1, 2022.

How can I participate in the Harmony Biosciences conference call?

To participate, dial (800) 225-9448 for domestic calls or +1 (203) 518-9708 for international calls.

Where can I find more information about Harmony Biosciences?

More information can be found on their investor page at https://ir.harmonybiosciences.com/

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

HRMY Rankings

HRMY Latest News

HRMY Stock Data

1.94B
38.55M
11.62%
93.1%
10.17%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PLYMOUTH MEETING